Autorisation d’accès précoce refusée à la spécialité TEPEZZA (téprotumumab) dans l'indication « traitement des patients adultes atteints d’ophtalmopathie basedowienne modérée à sévère ».
See also
HAS opinions and decisions
26/02/2025
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
KtbbQmtUCtMr39PH
